Revolution Medicines Statistics
Total Valuation
RVMD has a market cap or net worth of $6.55 billion. The enterprise value is $4.79 billion.
Important Dates
The next estimated earnings date is Wednesday, May 7, 2025, after market close.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RVMD has 185.91 million shares outstanding. The number of shares has increased by 48.24% in one year.
| Current Share Class | 185.91M |
| Shares Outstanding | 185.91M |
| Shares Change (YoY) | +48.24% |
| Shares Change (QoQ) | +4.14% |
| Owned by Insiders (%) | 2.37% |
| Owned by Institutions (%) | 97.78% |
| Float | 168.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.07 |
| P/TBV Ratio | 3.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.20, with a Debt / Equity ratio of 0.06.
| Current Ratio | 14.20 |
| Quick Ratio | 13.97 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -29.33% and return on invested capital (ROIC) is -19.97%.
| Return on Equity (ROE) | -29.33% |
| Return on Assets (ROA) | -18.66% |
| Return on Invested Capital (ROIC) | -19.97% |
| Return on Capital Employed (ROCE) | -28.80% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.12M |
| Employee Count | 534 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -753,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +17.75% in the last 52 weeks. The beta is 1.46, so RVMD's price volatility has been higher than the market average.
| Beta (5Y) | 1.46 |
| 52-Week Price Change | +17.75% |
| 50-Day Moving Average | 40.31 |
| 200-Day Moving Average | 44.59 |
| Relative Strength Index (RSI) | 40.32 |
| Average Volume (20 Days) | 1,262,359 |
Short Selling Information
The latest short interest is 16.65 million, so 8.96% of the outstanding shares have been sold short.
| Short Interest | 16.65M |
| Short Previous Month | 15.84M |
| Short % of Shares Out | 8.96% |
| Short % of Float | 9.90% |
| Short Ratio (days to cover) | 11.88 |
Income Statement
| Revenue | n/a |
| Gross Profit | -592.23M |
| Operating Income | -689.52M |
| Pretax Income | -522.73M |
| Net Income | -600.09M |
| EBITDA | -683.00M |
| EBIT | -689.52M |
| Earnings Per Share (EPS) | -$3.58 |
Full Income StatementBalance Sheet
The company has $2.29 billion in cash and $135.84 million in debt, giving a net cash position of $2.15 billion or $11.58 per share.
| Cash & Cash Equivalents | 2.29B |
| Total Debt | 135.84M |
| Net Cash | 2.15B |
| Net Cash Per Share | $11.58 |
| Equity (Book Value) | 2.27B |
| Book Value Per Share | 12.19 |
| Working Capital | 2.16B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$557.44 million and capital expenditures -$10.31 million, giving a free cash flow of -$567.74 million.
| Operating Cash Flow | -557.44M |
| Capital Expenditures | -10.31M |
| Free Cash Flow | -567.74M |
| FCF Per Share | -$3.05 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |